Prohibits procurement of opioid antidotes from certain entities.
Summary
S3904 would direct New Jersey state purchasing authorities to limit procurement of opioid antidotes, including naloxone and other FDA-approved overdose reversal drugs, to manufacturers and distributors that have not been parties to state settlements related to the opioid epidemic. The bill applies to the Division of Purchase and Property in the Department of the Treasury and to any state agency with contracting authority, and it bars entities that settled opioid-related claims with any state government, along with their affiliates and subsidiaries, from participating in solicitations or selling opioid antidotes to the State.
The bill also requires that requests for proposals for opioid antidotes be issued only to eligible entities and that purchases, including those made with available federal funds, be made only from selected vendors that meet the same settlement-free standard. An exception preserves existing settlement obligations: if a company agreed before September 1, 2024, to provide opioid antidotes as part of a settlement, it may continue doing so until those obligations are completed. The act would take effect immediately and would supplement Title 52 of the Revised Statutes.
Impact
The bill would change state procurement policy by imposing a vendor eligibility restriction for opioid overdose medications. It would not regulate private sales generally, but it would bar the State from soliciting or purchasing opioid antidotes from companies that have settled opioid-related claims with any state government, thereby affecting procurement practices across executive, legislative, and judicial branch agencies with purchasing authority. The measure also creates a grandfathering provision for preexisting settlement-based supply commitments entered into before September 1, 2024.
Sentiment
Based on the bill text and the absence of committee testimony or recorded votes in the provided materials, the overall sentiment appears strongly supportive of a punitive, accountability-focused approach toward companies associated with the opioid epidemic. The sponsor’s findings frame the bill as a way to ensure the State buys overdose-reversal medications only from manufacturers and distributors not implicated in opioid-related settlements. No contrary views are documented in the supplied record.
Contention
The main point of contention is likely the bill’s exclusion of companies that have settled opioid-related claims, even if they are major suppliers of naloxone or other opioid antidotes. Supporters would view the restriction as an ethical procurement policy that avoids doing business with entities tied to the epidemic, while opponents could argue it narrows the vendor pool, complicates procurement, or risks supply and pricing issues for a critical public health medication. The bill’s carve-out for preexisting settlement obligations suggests an effort to avoid disrupting current supply arrangements, but it also highlights the tension between punitive policy goals and continuity of access.